Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning

Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

Bone Marrow Transplantation volume 35, pages 233–241 (2005)Cite this article

Summary:

Treosulphan has recently demonstrated antileukaemic activity and potent haematopoietic stem cell toxicity. Dose-escalated treosulphan (3 × 12 or 3 × 14 g/m2) combined with cyclophosphamide (Cy) was chosen for a new preparative regimen before allogeneic haematopoietic stem cell transplantation in 18 patients (median age 44, range 19–64 years) with haematological malignancies, considered ineligible for other myeloablative preparative regimens. Pharmacokinetic studies demonstrated rapid treosulphan plasma clearance and a dose-dependent increase of its maximum plasma concentrations and area under the concentration–time curves. Rapid and sustained white blood cell and platelet recovery and full donor chimerism was attained in all evaluable patients. Nonhaematological regimen-related CTC grades 3–4 adverse events were transient and predominantly consisted of cardiac (28%), gastrointestinal (39%), and hepatic (39%) toxicities. The 1-year nonrelapse mortality was 22%. Principal causes of transplant-related lethal events were infections in three of four affected patients. Only one patient died from regimen-related cardiac toxicity. The 1-year relapse estimate is 22%, overall and progression-free survival estimates are 67 and 56%, respectively. In conclusion, this new treosulphan and Cy combination is an effective, comparatively well-tolerated myeloablative preparative regimen even in patients with an increased risk for regimen-related toxic complications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Harstrick A, Wilke H, Eberhardt W et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153–156.

    Google Scholar 

  2. Scheulen ME, Hilger RA, Oberhoff C et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209–4216.

    CAS  Google Scholar 

  3. Baynes RD, Dansey RD, Klein JL et al. A phase I trial of escalating treosulfan in combination with high-dose melphalan and dacarbazine (TMD) with peripheral blood progenitor cell transplant (PBPCT) in recurrent metastatic ovarian and breast cancer. Blood 2000; 96: 170a (Abstr. 731).

    Google Scholar 

  4. Westerhof GR, Ploemacher RE, Boudewijn A et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470–5478.

    CAS  Google Scholar 

  5. Ploemacher RE, Westerhof GR, Blokland I et al. Treosulfan as an alternative conditioning agent in bone marrow transplantation. Bone Marrow Transplant 2000; 25 (Suppl. 1) (Abstr. P421).

  6. Ploemacher RE, Johnson KW, Rombouts EJC et al. Addition of treosulfan in a non-myeloablative conditioning regimen results in enhanced chimerism and immunological tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 236–245.

    Article  CAS  Google Scholar 

  7. van Pel M, van Breugel DWJG, Vos W et al. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC-barriers. Bone Marrow Transplant 2003; 32: 15–22.

    Article  CAS  Google Scholar 

  8. Andersson G, Illigens BMW, Johnson KW et al. Non-myeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 2003; 101: 4305–4312.

    Article  CAS  Google Scholar 

  9. Van Pel M, van Breugel DWJG, Vos W et al. Towards a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone Marrow Transplant 2004; 33: 1–7.

    Article  Google Scholar 

  10. Meinhardt G, Dayyani F, Jahrsdörfer B et al. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Hematol 2003; 122: 1–8.

    Article  Google Scholar 

  11. Schmidmaier R, Oellerich M, Baumgart J et al. Treosulfan induced apoptosis in AML cells is accompanied by translocation of PKC delta and enhanced by Bryostatin-1. Exp Hematol 2004; 32: 76–86.

    Article  CAS  Google Scholar 

  12. Topaly J, Fruehauf S, Ho AD, Zeller WJ . Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 2002; 86: 1487–1493.

    Article  CAS  Google Scholar 

  13. Fichtner I, Becker M, Baumgart J . Antileukemic activity of treosulfan in xenografted human acute lymphoblastic leukemias (ALL). Eur J Cancer 2003; 39: 801–807.

    Article  CAS  Google Scholar 

  14. Weissert R, Wiendl H, Pfrommer H et al. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalo-myelitis and human lymphocytes. J Neuroimmunol 2003; 144: 28–37.

    Article  CAS  Google Scholar 

  15. Casper J, Knauf W, Kiefer T et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic blood stem cell transplantation. Blood 2004; 103: 725–731.

    Article  CAS  Google Scholar 

  16. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  17. Hilger RA, Harstrick A, Eberhardt W et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99–104.

    Article  CAS  Google Scholar 

  18. Klein JP, Moeschberger ML . Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn. Statistics for Biology and Health, Springer: Berlin, 2003.

    Google Scholar 

  19. Heinzel G, Woloszczak R, Thomann P . TOPFIT Version 2.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Fischer/VCH: Stuttgart, 1993.

    Google Scholar 

  20. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  Google Scholar 

  21. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231–234.

    Article  CAS  Google Scholar 

  22. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  Google Scholar 

  23. McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043–2048.

    Article  CAS  Google Scholar 

  24. Hassan M, Ljungman P, Ringdén O et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915–924.

    Article  CAS  Google Scholar 

  25. Hartman A-R, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439–443.

    Article  CAS  Google Scholar 

  26. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the significant contribution of C Buchsteiner and C Peiske for data management.

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital Essen, Germany

    D W Beelen & R Trenschel

  2. Department of Haematology/Oncology, Clinic for Internal Medicine, University of Rostock, Germany

    J Casper & M Freund

  3. Department of Internal Medicine (Tumor Research), University Hospital Essen, Germany

    R A Hilger & M E Scheulen

  4. Department of Haematology/Oncology, Bone Marrow Transplantation Unit, Idar-Oberstein, Germany

    N Basara & A A Fauser

  5. Department of Internal Medicine, Medical School Hanover, Hanover, Germany

    B Hertenstein

  6. medac GmbH, Wedel, Germany

    H A Mylius, J Baumgart & U Pichlmeier

  7. Department of Bone Marrow Transplantation, Medical Clinic I, University of Regensburg, Germany

    J R Hahn & E Holler

Authors
  1. D W Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Trenschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R A Hilger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M E Scheulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Basara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A A Fauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Hertenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H A Mylius
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Baumgart
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. U Pichlmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J R Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E Holler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D W Beelen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beelen, D., Trenschel, R., Casper, J. et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35, 233–241 (2005). https://doi.org/10.1038/sj.bmt.1704784

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704784

Keywords

This article is cited by

Search

Advanced search

Quick links